Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease

Phase 4

Completed

• Conditions: Primary Disease
• Interventions: Drug: VPRIV

• Registration Number: NCT03702361
• Lead Sponsor: Shaare Zedek Medical Center

Brief Summary

During the past two years, the investigator has performed succsefully an IIR wherein patients with GD, previously treated with velaglucerase alfa ERT were gradually switched to a 10 minutes (rapid) administration of the same ERT. The success was expressed as safety (no clinically meaningful AEs, no antibodies detected, home therapy), efficacy ("lack of deterioration") and patients' satisfaction. The latter was based not just on specific questionnaires and analog scales, but particularly by the patients' sharing the experience with other patients and consequently repeated requests by many to switch to a rapid administration of their ERT.

Therefore, the investigator is hereby proposing to investigate the safety and efficacy of a 10 minutes administration of velaglucerase alfa in a cohort of treatment-naive patients.

The current VPRIV label is restricted to a dosage of 60 units/kg body weight every other week (60 units/kg EOW) - this dose will be used throughout the study period. The enzyme will be provided by Shire, which will also provide a research grant for the conduction of the trial.

Detailed Description

Protocol:

Study Design: This will be a single-center, open-label trial to assess the safety and efficacy of rapid administration of velaglucerase alfa (VPRIV) to treatment-naive patients with type I Gaucher disease. The first six infusions will be administered in the hospital: the first three infusions within 60, 30 and 20 minutes each, with the beginning of a 10 minutes administration from infusion #4. Following the three uneventful administration of the 10 minutes in the hospital, the bi-weekly ERT will continue as home therapy, as outlined in the protocol. The duration of the study will be 12 months, with an extension pending positive results.

Number of Patients: 15. The first ten patients will be adults, and then children will be allowed to enroll in the trial.

Study Timeline

• Study First Submitted: 2018-08-06
• Study Start: 2018-09-04
• Study First Submitted QC: 2018-10-09
• Study First Posted: 2018-10-11
• Primary Completion: 2019-09-30
• Status Verified: 2021-03
• Study Completion: 2021-03-18
• Last Update Submitted: 2021-03-18
• Last Update Posted: 2021-03-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Males and females, 18 years or older for the first ten adult patients; 6 years or older for the last five patients.

  • Confirmed enzymatic diagnosis of Gaucher disease with a defined genotype and elevated biomarker LysoGb1, performed at CentoGene using DBS methodology.
  • Indications for ERT will be guided by fulfilling the MOH criteria.
  • Female patients of child-bearing potential who agree to use a medically acceptable method of contraception.
  • Patients who have not received ERT or SRT in the past or Patients who have not received ERT or SRT in the past 12 months and have a negative anti-glucocerebrosidase antibody

Exclusion Criteria

• Currently taking another experimental drug for any condition

  • Presence of neurologic signs and symptoms characteristic of Type 2 or Type 3 Gaucher disease
  • Pregnant or nursing
  • Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Rapid infusion of Vpriv	VPRIV	Rapid intravenous infusion of velaglucerase alfa (VPRIV) in treatment-naive patients with type 1 Gaucher disease

Primary Outcome Measures

Name	Time	Method
Percent change from baseline in spleen volume measured by MRI	12 months.	Percent change from baseline

Secondary Outcome Measures

Name	Time	Method
Change from baseline in Hemoglobin	12 months	Percent change from baseline
Change from baseline in platelet count	12 months	Percent change from baseline
Change from baseline in Lyso-GB1	12 months	Percent change from baseline
Change from baseline in liver volume	12 months	Percent change from baseline
Change from baseline 10% reduction in spleen volume	6 months	Percent change from baseline

Trial Locations

Locations (1)

Michal Becker- Cohen; 🇮🇱 Jerusalem, Please Select..., Israel